Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/22/19 → 5/27/23 |
Funding
- Vertex Pharmaceuticals Inc: $83,776.00
VS18-445-113: A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis
- Danov, Zoran (PI)
- Anstead, Michael (CoI)
- Pancham, Krishna (Former PI)